Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Recruiting · NCT06862739 · Interventional (participants receive a specific treatment) · Lead sponsor: Nabiqasim Industries (Pvt) Ltd
View the official record on ClinicalTrials.gov →Interventions studied
Empagliflozin+Linagliptin+Metformin
What this trial is about
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients of any gender
- Patients aged between 18-80 years
- Patients having HbA1c 8 % or above
- Patients diagnosed with type II diabetes (more than at least 06 months)
- Patients already on at least 02 or more anti-diabetic agents
- Patients not allergic to empagliflozin, linagliptin, or metformin
Exclusion criteria
- Patients with age less than 18
- Patients with Type-I diabetes
- Patients having diabetes for less than 06 months
- Patients on GLP-1 and GIP
- Patients who are pregnant or lactating females
- Patients with decompensated chronic liver disease (DCLD)
- Patients with eGFR less than 30 ml
- Patients with end-stage heart failure (NYHA Class 4)
- Patients who are allergic to empagliflozin, linagliptin, or metformin
- Patients who are not willing to consent
- Patients who are unable to give medical history
Where it is running
2 locations listed.
- Faisalabad clinics - Faisalabad, Punjab Province, Pakistan
- Aap ka Clinic - Lahore, Punjab Province, Pakistan